Kymera Therapeutics

32 articles with Kymera Therapeutics

• Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit

  10/12/2020

  Kymera Therapeutics, Inc., a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15.

• Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa

  10/9/2020

  Results support clinicaldevelopment of IRAK4-targeted protein degrader in hidradenitis suppurativa (HS)and other IL-1R/TLR-driven autoimmune and inflammatory diseases, with Phase 1 trial on track for start in 2021

• Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

  9/14/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference at 5:00 p.m. ET on

• Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

  8/27/2020

  Kymera Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, announced the appointment of Richard Chesworth, PhD, to the role of Chief Scientific Officer.

• Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

  8/25/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the closing of its upsized initial public offering of 9,987,520 common shares, including the exercise in full by the underwriters of their option to purchase up to 1,302,720

• Kymera Therapeutics Announces Pricing of Upsized Initial Public Offering

  8/21/2020

  Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, t

• Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients

  7/9/2020

  Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments

• 

  Kymera and Sanofi Enter Anti-Inflammatory Deal Worth More than $2 Billion

  7/9/2020

  They will focus on developing and commercializing protein degrader therapies that target IRAK4 in immune-inflammatory diseases, such and rheumatoid arthritis.

• Kymera Therapeutics to Disclose IRAKIMiD Degrader Program and Present Preclinical Data Demonstrating Potent Immunomodulatory and Antitumor Activity for its Novel STAT3 Degraders in Immuno-oncology

  6/11/2020

  Kymera Therapeutics, Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced that it will present preclinical data on its potent and highly selective STAT3 degraders as well as the first data from its novel IRAKIMiD degraders combining IRAK4 and IMiD substrate degradation.

• Kymera Therapeutics Initiates Enrollment in Non-Interventional Trial Evaluating IRAK4 Role in Patients with Hidradenitis Suppurativa and Atopic Dermatitis

  6/3/2020

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, today announced that the company has initi

• Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform

  3/12/2020

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to invent breakthrough protein degrader medicines for patients, announced the closing of a $102 million Series C financing.

• 

  With an Eye on the Clinic, Atlas-Backed Kymera Secures $102 Million

  3/12/2020

  Kymera Therapeutics closed a $102 million Series C funding round to continue advancing the company’s lead targeted protein degradation asset for oncology and immunology.

• Kymera Therapeutics to Present Preclinical Data on its First-in-Class Selective and Potent Oral IRAK4 Degraders in Cutaneous Inflammation

  2/5/2020

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present preclinical data demonstrating that oral daily dosing of its IRAK4 degraders completely suppressed IRAK4 protein expression in skin and immune cells and inhibited cutaneous inflammation.

• Kymera Therapeutics to Present Preclinical Data Demonstrating Potent Antitumor Activity by a Selective STAT3 Degrader in Hematologic Malignancies at the American Society of Hematology Annual Meeting

  12/9/2019

  Kymera Therapeutics Inc., today announced the company will present new preclinical data showing the further characterization of novel, highly selective and potent degraders of STAT3 with activity across multiple hematologic malignancies including ALK-positive anaplastic large cell lymphoma (ALK+ ALCL),

• 

  BioSpace Movers & Shakers, Nov. 22

  11/22/2019

  Pharma and biotech companies strengthen their leadership teams and boards with this week's appointments.

• Kymera Therapeutics Promotes Nello Mainolfi, PhD, to Chief Executive Officer

  11/20/2019

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough therapies for patients, today announced Kymera Co-founder, President and Chief Scientific Officer Nello Mainolfi, PhD, has been promoted to President and Chief Executive Officer effective immediately

• Kymera Therapeutics to Present Preclinical Data on its First-in-Class IRAK4 Degraders Demonstrating Robust Inhibition of Inflammatory Responses and Superiority to IRAK4 Kinase Inhibitors

  11/11/2019

  Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to discover breakthrough medicines for patients, today announced the company will present new preclinical data showing its first-in-class selective and potent oral IRAK4 degraders demonstrate broad and robust in vitro and in vivo inhibition of the toll-like receptor (TLR) and Interleukin-1 receptor (IL-1R) pathways underlying the pathogenesis of many inflammatory and autoimmune diseases.

• Kymera Therapeutics to Present Preclinical Data Demonstrating the Potency and Antitumor Activity of a Selective STAT3 Degrader at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

  10/17/2019

  Kymera Therapeutics Inc. announced the company will present preclinical data showing the discovery and characterization of novel, selective, and potent degraders of STAT3, a transcriptional regulator linked to numerous cancers and other diseases.

• Kymera Therapeutics Announces Leadership Transitions

  7/15/2019

   Kymera Therapeutics Inc., a biotechnology company advancing the field of targeted protein degradation to create breakthrough therapies for previously untreatable diseases, today announced key leadership transitions

• Kymera Therapeutics to Present New Preclinical Data for its First-In-Class Oral IRAK4 Degrader in MYD88-Mutant B Cell Lymphoma at the 15th International Conference on Malignant Lymphoma

  6/19/2019

  KYM-001 causes potent and selective IRAK4 protein knockdown and regression of OCI-LY10 tumor xenografts, both alone and in combination with BTK inhibition